Arcturus Therapeutics Announces $50 Million Investment by Meiji Seika Pharma as Part of Expanded Collaboration
Proceeds to accelerate development of ARCT-2601 for OTC Deficiency and clinically validate Arcturus’ LUNAR 2.0™ next-generation mRNA platform
Under the terms of the securities purchase agreement, Meiji will purchase
Concurrent with the execution of the securities purchase agreement, Arcturus and Meiji entered into an exclusive license agreement relating to the application of ARCT-154 technology for an undisclosed therapeutic area, and a Memorandum of Understanding (MOU) establishing the principal terms for a potential collaboration and license agreement for a pandemic preparedness and response program in
“We are pleased to expand our relationship with Meiji as we advance innovative mRNA medicines and seek to deliver value to patients. The investment, together with the license agreement and the pandemic preparedness MOU, reflects Meiji’s confidence in our development capabilities and the potential of our technology platform,” said
About Arcturus
Founded in 2013 and based in
About Meiji Seika Pharma
Meiji Seika Pharma, since it launched penicillin in 1946, has been providing efficacious and high-quality pharmaceutical products including therapeutics and vaccines for infectious diseases, therapeutics for central nervous system diseases and hematologic disorders and generic drugs, to meet various medical needs. The company continues to advance global health by investing in next-generation innovation and strategic cross-border partnerships.
https://www.meiji.com/global/pharmaceuticals/
Forward Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact included in this press release, are forward-looking statements, including those regarding strategy, future operations, the likelihood of the Company’s pipeline (including ARCT-032, ARCT-810 and ARCT-2601), the use of the proceeds from the investment in Arcturus, the likelihood of and timing for development of ARCT-2601 and for the clinical validation of LUNAR 2.0, the likelihood of and timing for entering into a definitive agreement based on the Memorandum of Understanding, and the impact of general business and economic conditions. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements such as the foregoing and you should not place undue reliance on such forward-looking statements. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements, including those discussed under the heading "Risk Factors" in Arcturus’ most recent Annual Report on Form 10-K, and in subsequent filings with, or submissions to, the SEC, which are available on the SEC’s website at www.sec.gov. Except as otherwise required by law, Arcturus disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261116054386/en/
Arcturus Therapeutics
Public Relations & Investor Relations
Neda Safarzadeh
VP, Head of IR/PR/Marketing
(858) 900-2682
IR@ArcturusRx.com
Source: Arcturus Therapeutics Holdings Inc.